- Innovation Insights
- Business Professionals
- IP Strategists
- IP Practitioners
- Products & Services
- About PatentSight
As the global research community is scrambling to develop solutions and help the world recover from the impact of Covid-19, we should not stay blind to other medical risks on the horizon which should be addressed. Chief among these is drug resistant bacteria, a risk which could potentially lead to almost an equal impact as by the current pandemic.
Tuberculosis for e.g. is a global disease caused by bacterial infection, found in almost every country in the world. It is the leading (infectious) cause of death worldwide, killing someone approximately every 21 seconds — for reference, about 1.5 million deaths in 2018 alone; compared to the approximately 450,000 deaths due to the Covid-19 virus in the last 6 months. Consuming antibiotics at a higher rate is not a sustainable solution as the research community has observed an increase in the evolution of drug resistant strains of bacteria, that has been linked to excessive use of such anti-bacterial drugs.
In the US alone, in 2012, animals consumed more than twice as many medically important antibiotics as humans. Such a heavy dependency and use of anti-bacterial drugs often lead to an increasing number of antibiotic-resistant bacteria like some strains of E.Coli, etc. or antimicrobial resistance (AMR) with multiple or totally resistant pathogens.
We take a look at the patent landscape of antibiotics to identify global leaders developing the latest innovation in this technology. Join our webinar to find out which company/companies own the strongest patents in this field, and thus are prepared to save the world from a drug resistant bacteria, if it comes to that.
Using our proven metrics, in this webinar, the presenters will examine and discuss:
In addition, experience how the powerful visualization features offered by PatentSight, help to quickly identify the strongest players in any specific IP landscape.
Gene Quinn is the President and founder of IPWatchdog.com, a patent attorney, law professor, and leading commentator on patent law and innovation policy. Gene’s writing typically focuses on pending legislation, rule making at the United States Patent and Trademark Office, and general commentary about the state of the industry. Gene practices patent law with Widerman Malek, and the majority of his patent practice is focused on software patents and Internet innovations. Since 2000 he has also been a principal lecturer in the PLI Patent Bar Review Course.
Dr. Dirk Caspary is a Senior Consultant at PatentSight. His strong analytical skills in combination with his 'outside-the-box' thinking, give Dirk's clients an edge over their competitors. His academic background in chemistry and a focus on physical chemistry of solids, led him to work for five years in the semiconductor industry and more than a decade as a senior process analyst and IP consultant before joining PatentSight.
June 25th 2020 | 18:00 CET | 12:00 pm (noon) ET